Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of JNJ-56136379 with or without nucleos(t)ide analogs in chronic hepatitis B virus infection
jRCT2080223869Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of bersacapavir in Chronic Hepatitis B (CHB) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Efficacy of JNJ-56136379 (monotherapy and combination) on HBV virologic markers, Safety and tolerability of JNJ-56136379 and 1 more. Started Apr 2018; status: completed.
02
Drugs
bersacapavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080223869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223869.